Business Context and Reporting Period
Company: Microbot Medical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 24, 2026
Reporting Period: Single event date (March 24, 2026)
Business Context: The filing discloses a Regulation FD event regarding the publication of a clinical study article in the Journal of Vascular and Interventional Radiology (JVIR). The article, titled "In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study," features Dr. Francois Cornelis, who served as the Lead Principal Investigator for the LIBERTY ACCESS PVI Pivotal Study.
Key Financial Metrics
This Form 8-K is a disclosure of a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing does not report material changes to financial performance or operational metrics compared to a prior period. The material change disclosed is the publication of the aforementioned clinical study article, which serves as a milestone for the Company's endovascular robotic system development.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) by reference but does not include specific forward-looking guidance, financial outlook, or detailed management commentary within the body of the 8-K text.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text. The document explicitly states that the information furnished shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be deemed an admission as to the materiality of the information.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for detailed results of the JVIR study.
- Verify the specific findings and success rates of the "LIBERTY ACCESS PVI Pivotal Study" mentioned in the article.
- Confirm the regulatory implications of the published study for the Company's product approval timeline.
- Check subsequent filings for any financial impact or updated guidance resulting from this clinical milestone.